Cerivastatin, genetic variants, and the risk of rhabdomyolysis

The withdrawal of cerivastatin involved an uncommon but serious adverse reaction, rhabdomyolysis. The bimodal response, rhabdomyolysis in a small proportion of users, points to genetic factors as a potential cause. We conducted a case-control study to evaluate genetic markers for cerivastatin-associ...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmacogenetics and genomics Jg. 21; H. 5; S. 280
Hauptverfasser:	Marciante, Kristin D, Durda, Jon P, Heckbert, Susan R, Lumley, Thomas, Rice, Ken, McKnight, Barbara, Totah, Rheem A, Tamraz, Bani, Kroetz, Deanna L, Fukushima, Hisayo, Kaspera, Rüdiger, Bis, Joshua C, Glazer, Nicole L, Li, Guo, Austin, Thomas R, Taylor, Kent D, Rotter, Jerome I, Jaquish, Cashell E, Kwok, Pui-Yan, Tracy, Russell P, Psaty, Bruce M
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.05.2011
Schlagworte:	Adult Aged Aged, 80 and over Aryl Hydrocarbon Hydroxylases - genetics Case-Control Studies Cytochrome P-450 CYP2C8 Female Genetic Variation Genome-Wide Association Study Glucuronosyltransferase - genetics Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Liver-Specific Organic Anion Transporter 1 Male Middle Aged Organic Anion Transporters - genetics Polymorphism, Single Nucleotide Pyridines - adverse effects Pyridines - therapeutic use Rhabdomyolysis - chemically induced Rhabdomyolysis - genetics Risk Ryanodine Receptor Calcium Release Channel - genetics
ISSN:	1744-6880, 1744-6880
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!